Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for subependymal giant cell astrocytoma in tuberous sclerosis
IRCT20240112060688N1Phase 4Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of everolimus in tuberous sclerosis complex (TSC) and subependymal giant cell astrocytoma (SEGA), sponsored by Shiraz University of Medical Sciences. Started Dec 2024; status: completed.
02
Drugs
everolimus
03
Conditions
tuberous sclerosis complex (TSC)subependymal giant cell astrocytoma (SEGA)
Beyond the preview
Go deeper on IRCT20240112060688N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240112060688N1.